NVCR vs IDXX vs HOLX vs MASI

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: Masimo Corporation grew EPS 51. 0% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 22. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.